Clinical trialNCT05205070UnknownPhase 2Interventional

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

SponsorAnaptysBio, Inc.Enrollment45Alopecia Areata

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bruce Randazzo, MD
AnaptysBio, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

10-105
Birmingham, Alabama, United States
Recruiting
Site10-103
Encinitas, California, United States
Recruiting
Site 10-113
Northridge, California, United States
Recruiting
Site 10-115
Chicago, Illinois, United States
Recruiting
10-104
Indianapolis, Indiana, United States
Recruiting
Site 10-109
Plainfield, Indiana, United States
Recruiting
Site 10-116
Louisville, Kentucky, United States
Recruiting
Site 10-117
Clarkston, Michigan, United States
Recruiting
Site 10-111
New York, New York, United States
Recruiting
Site 10-101
Charlotte, North Carolina, United States
Recruiting
Site 10-102
Bexley, Ohio, United States
Recruiting
Site 10-106
Tulsa, Oklahoma, United States
Recruiting
10-107
Upper Saint Clair, Pennsylvania, United States
Recruiting
10-110
Houston, Texas, United States
Recruiting
Site 10-108
San Antonio, Texas, United States
Recruiting
Site 10-114
Kenosha, Wisconsin, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRosnilimab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Dec 2021
Primary completion: 19 Jan 2023
Completion: 19 Mar 2023
Last update posted: 10 May 2022
Registered enrollment: 45
Registry id: NCT05205070

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.